Fostamatinib for persistent/chronic adult immune thrombocytopenia | Immunotherapy
JCM | Free Full-Text | Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management
Novel therapies for immune thrombocytopenia - Kuter - 2022 - British Journal of Haematology - Wiley Online Library
Mechanism of Action | TAVALISSE HCP
Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion - Alessandro Lucchesi, Bruno Fattizzo, Valerio De Stefano, Marco Ruggeri, Sergio Siragusa, Nicola Vianelli, Francesco
IJMS | Free Full-Text | Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach
Recent advances in the mechanisms and treatment of immune thrombocytopenia - eBioMedicine
Favorable aspects and potential difficulties foreseen by the EP with... | Download Scientific Diagram
Mechanism of Action | TAVALISSE HCP
![PDF] Efficacy and mechanism of intravenous immunoglobulin treatment for immune thrombocytopenia in adults | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5c2330a7e20affaf506ba421407aa70a9a225a24/5-Figure1-1.png "PDF] Efficacy and mechanism of intravenous immunoglobulin treatment for immune thrombocytopenia in adults | Semantic Scholar")
PDF] Efficacy and mechanism of intravenous immunoglobulin treatment for immune thrombocytopenia in adults | Semantic Scholar
Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib - Nichola Cooper, Ivy Altomare, Mark R. Thomas, Phillip L. R. Nicolson, Steve P. Watson, Vadim Markovtsov, Leslie K. Todd,
Fostamatinib for persistent/chronic adult immune thrombocytopenia | Immunotherapy
Fostamatinib: A Review in Chronic Immune Thrombocytopenia | SpringerLink
g176401moi008.gif
Medicina | Free Full-Text | Immune Thrombocytopenic Purpura as a Hemorrhagic Versus Thrombotic Disease: An Updated Insight into Pathophysiological Mechanisms
Thrombopoietin receptor agonists: ten years later | Haematologica
Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406 | SpringerLink
![PDF] Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP) | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d711e8e86aeae763b8fc11f910a59ea4140c53c6/6-Figure1-1.png "PDF] Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP) | Semantic Scholar")
PDF] Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP) | Semantic Scholar
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach | Nature Reviews Rheumatology
Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy | Nature Reviews Clinical Oncology
Mechanism of Action | TAVALISSE HCP
COVID-19 :: Rigel Pharmaceuticals, Inc. (RIGL)
JCM | Free Full-Text | Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management
Frontiers | Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease
Rigel's fostamatinib successfully meets endpoint in chronic ITP trial
Fostamatinib for persistent/chronic adult immune thrombocytopenia | Immunotherapy
Frontiers | Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
